We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Master Clinical Trial Protocols Enable New Antibacterial Drug Development

Master Clinical Trial Protocols Enable New Antibacterial Drug Development

August 6, 2014

Conducting clinical trials with multiple drug candidates from different manufacturers simultaneously will be key to developing new antibacterial therapies, say experts seeking to address the growing problem of antibiotic resistance.

The use of a master clinical trial protocol provides consistent criteria and endpoints, and lets investigators share results on different pathogens across multiple infection sites, two features that can speed up the regulatory approval process, said Ohad Amit, head of infectious disease clinical statistics at GlaxoSmithKline.

Developing new antibiotics has become a priority of the FDA, as the pipeline for new antibiotics dries up and growing resistance to existing products confounds healthcare providers.

A trial testing four products at once, for example, could identify a candidate that proves to be particularly effective or ineffective, at which point it is either abandoned or moved to the next step in the approval process, Amit said at a July 31 joint meeting held by the FDA and the National Institutes of Health to spur antibiotic development.

Such a trial model may also overcome the problem of having very small patient pools to test therapies addressing multidrug-resistant pathogens.

For example, only 7,000 to 8,000 patients develop Acinetobacter or carbapenemase-resistant infections in the U.S. every year, said Henry Chambers, a professor of infectious diseases at the University of California, San Francisco. You would have to enroll every single one of them in order to reach the traditional sizes of control and active treatment arms, he said.

Because most of these patients are seriously ill and need immediate treatment, placebo-controlled trials are often unethical.

One strategy may be to base analyses on patient outcomes rather than clinical endpoints, which could demonstrate the superiority of one product over another. “If we can figure out a way to rank patients based on how they are treated and what happens to them, there are ways we might be able to incorporate a superiority trial design that will allow you to escape examining endpoints,” Chambers said.

The development of rapid diagnostic tests also will be essential in confirming patients’ infections to determine eligibility in future trials, he added. — Lena Freund

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Drugs Research and Development

    Upcoming Events

    • 28Sep

      The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

    • 28Sep

      Calculating Sample Size to Satisfy FDA Expectations

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 08Nov

      18th Annual FDA Inspections vSummit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

    • Artificial Womb Technology Not Yet Ready for Human Trials Adcomm Says

    • Top Concern for CBER is Marketing of Unapproved Biologics, Says FDA Official

    • FDA Deems Medline Industries’ Saline Solution Vial Recall as Class 1

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing